Competitive approaches to the determination of the prices of drugs in the 2024 elections

Competitive approaches to the determination of the prices of drugs in the 2024 elections

The future of drug pricing policies in the United States depends on the outcome of the 2024 elections, with Democratic and Republican candidates presenting distinct approaches. Vice President Kamala Harris aims to expand the Biden administration's existing policies, while former President Donald Trump's position remains less defined.

Harris has pledged to broaden the scope of Medicare drug price negotiations, a key achievement of the Biden presidency, to include more drugs and benefit a broader population. It intends to use the resulting savings to fund an ambitious new proposal to cover long-term home care under Medicare. This means a commitment to consolidate the efforts of the current administration to reduce drug costs and expand access to care.

On the contrary, Trump offered less details on his plans on drug prices. Although he conducted a campaign to reduce the costs of the prescriptions, his approach remains largely unclear. This lack of clarity leaves voters uncertain about the future of drug pricing policy under a potential Trump administration. The two candidates' contrasting approaches highlight the importance of this issue in the upcoming election and its potential impact on the affordability and accessibility of medications for Americans.

By Roger W. Watson

You May Also Like